Rob Brierley

Rob Brierley

@robbrierley.bsky.social

Editor-in-Chief, The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social. Views my own; reposting ≠ endorsement. #GastroSky #LiverSky #GISky #OncSky

1.3K followers527 following299 posts

Rob Brierley reposted

The National Union of Journalists
@nujofficial.bsky.social

Our members at The Lancet are taking further strike action for fair pay this week. Live coverage⬇️ https://www.nuj.org.uk/resource/lancet-strike-action-resumes-publication-impacted.html

nuj.org.ukLancet strike action resumes as publication impactedNUJ members at The Lancet are on strike for a second time over low pay, forming a picket outside the company’s London HQ this morning and carrying 'Fair Pay Now' and 'Solidarity For Science' placards and banners.

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

Research - Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study www.thelancet.com/journals/lan... #LiverSky #MedSky

thelancet.comPrevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort studyLiver fibrosis and steatotic liver disease are prevalent in community-dwelling Chinese adults, driven by metabolic factors and alcohol consumption. These findings identify chronic liver disease as a m...

Rob Brierley reposted

The Lancet Reg Health-Europe
@lancetrh-europe.bsky.social

The landscape of hepatocellular carcinoma in Europe is changing. Chaired by Prof David Pinato, the Series examines the evolving #HCC burden, persistent surveillance gaps, advances in treatment and inequalities in access to care. Read more 👇 shorturl.at/qo8g1

shorturl.atHepatocellular carcinoma in EuropeHepatocellular carcinoma (HCC) is an increasing and evolving health challenge in Europe, shaped by changing liver disease epidemiology, persistent gaps in surveillance, and rapid advances in treatment...

Rob Brierley reposted

The Lancet Neurology
@thelancetneuro.bsky.social

New online in @lancetrh-europe.bsky.social, a Review of neurogenic gastrointestinal, urinary, and sexual symptoms in multiple sclerosis, aiming to translate evidence into a pragmatic model of care tailored to the realities of European clinical practice www.thelancet.com/journals/lan...

thelancet.comNeurogenic gastrointestinal, urinary, and sexual dysfunction in multiple sclerosis: a multidisciplinary framework for clinical practiceNeurogenic gastrointestinal, urinary, and sexual symptoms are highly prevalent in people with multiple sclerosis and substantially impair quality of life, daily functioning, and psychosocial well-bein...

Rob Brierley reposted

The Lancet
@thelancet.com

🔔 Discover The Lancet Surgery & Anaesthesiology, a new journal with a sharp clinical focus, dedicated to advancing science across the full extent of #surgery, #anaesthesiology, and #perioperative specialties, across the age spectrum, and across the globe: spkl.io/633237JQbc

Rob Brierley reposted

The Lancet Neurology
@thelancetneuro.bsky.social

Replying to @thelancetneuro.bsky.social

And you can read more about Epstein-Barr virus (EBV) and multiple sclerosis (MS) in a Rapid Review, covering new insights into how EBV might cause MS and the potential for future prevention and treatment www.thelancet.com/journals/lan...

thelancet.comEpstein–Barr virus and multiple sclerosis: from associations to mechanisms to potential therapiesEpstein–Barr virus, a widespread herpesvirus that establishes lifelong latency after primary infection, has emerged in serological and epidemiological studies as a strong and consistent risk factor fo...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, placebo-controlled, phase 2 trial www.thelancet.com/journals/lan... #LiverSky #MedSky

thelancet.comThe glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multic...In this prespecified 12-week primary analysis, DD01 produced rapid reductions in liver fat compared with placebo, supporting further evaluation in long-term studies.

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

New - Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2 randomised controlled trial www.thelancet.com/journals/lan... #LiverSky #MedSky

thelancet.comEfficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-b...In participants with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, the combination of zalfermin 30 mg plus semaglutide 2·4 mg did not significantly increase the...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕Results from RELIEVE UCCD - efficacy and safety of duvakitug in patients with Crohn's disease or ulcerative colitis UC - www.thelancet.com/journals/lan... CD - www.thelancet.com/journals/lan... #GastroSky #MedSky #IBDSky

thelancet.comEfficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trialDuvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis.

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial www.thelancet.com/journals/lan... #GastroSky #OncSky #MedSky #AI

thelancet.comArtificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trialCADe-assisted colonoscopy did not show the absolute improvement in adenoma detection rate that was assumed in the prespecified sample-size calculation. CADx did not clearly improve lesion differentiat...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial www.thelancet.com/journals/lan... #GastroSky #MedSky

thelancet.comDupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trialThe improvement of histological outcomes of eosinophilic gastritis with dupilumab in this proof-of-concept study shows type 2 inflammatory involvement in the disease and the potential value of dupilum...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕 Research | Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial www.thelancet.com/journals/lan... #GastroSky #OncSky #rectalcancer

thelancet.comAdjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trialNon-inferiority of adjuvant chemoradiotherapy compared with cTME for 3-year locoregional recurrence could not formally be demonstrated. However, loss of equipoise hampered patient accrual, precluding ...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729–001): a phase 1a/b trial www.thelancet.com/journals/lan... #LiverSky #MedSky #IDSky #HepSky #MicroSky

thelancet.comThe small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729–001): a phase 1a/b trialSingle and multiple doses of imdusiran were safe and well tolerated in healthy individuals and in individuals with chronic hepatitis B, supporting drug development of imdusiran as a future treatment t...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

Review - Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice www.thelancet.com/journals/lan... #OncSky #MedSky #GastroSky

thelancet.comManagement of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practiceColorectal cancer predominantly affects older adults (ie, those aged 70 years or older). Along with shifting demographic trends, the number of patients with colorectal cancer in this age group is esti...

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕Viewpoint - Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality? www.thelancet.com/journals/lan... #GastroSky #MedSky #IBDSky

thelancet.comBreaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ceili...

Rob Brierley reposted

The Lancet
@thelancet.com

🆕 Introducing The Lancet Regional Health – Eastern Mediterranean, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in the Eastern Mediterranean. Discover the new addition to The Lancet Group at: spkl.io/63328AFIyw #medsky

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕 Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial www.thelancet.com/journals/lan... #GastroSky #OncSky #SurgSky

thelancet.comRobot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trialIn patients with resectable oesophageal squamous cell carcinoma, robot-assisted oesophagectomy was non-inferior, and seemed superior, to thoracoscopic oesophagectomy in terms of 5-year overall surviva...

Rob Brierley reposted

The Lancet Reg Health-Europe
@lancetrh-europe.bsky.social

Even with universal health insurance, inequalities persist. A Dutch study of >30 000 gastroesophageal cancer patients shows lower-income groups are less likely to receive surgery or systemic therapy—and have poorer survival. @amsterdamumc.bsky.social www-tinyurl.com/a296ab1e

www-tinyurl.comSocioeconomic disparities in treatment and survival of oesophageal and gastric cancer in the Netherlands: a nationwide population-based studyDespite universal health insurance, socioeconomic disparities in treatment and survival of gastroesophageal cancer patients persist in the Netherlands, reflecting not inequitable access but broader li...

Rob Brierley reposted

The Lancet
@thelancet.com

Primary sclerosing cholangitis is a rare liver disease, characterised by biliary inflammation and fibrosis. A new Seminar explores the clinical features, pathogenesis, and challenges and opportunities in managing the disease: spkl.io/63326A0F5O

Rob Brierley reposted

The Lancet Gastroenterology & Hepatology
@lancetgastrohep.bsky.social

🆕 The burden of chronic hepatitis B and C in 2022 and progress towards elimination: a global report www.thelancet.com/journals/lan... #LiverSky #IDSky #HepSky #MedSky

thelancet.comThe burden of chronic hepatitis B and C in 2022 and progress towards elimination: a global reportViral hepatitis represents a substantial burden of infectious disease globally, comparable with that caused by tuberculosis. Progress towards global hepatitis elimination is currently insufficient to ...